Last reviewed · How we verify
NCT03866590: PIECE
Pyruvate Kinase Deficiency Epidemiological Study (PIECE)
trial in Pyruvate Kinase Deficiency in 75 participants. Completed in 31 May 2021.
31 May 2021
Quick facts
| Lead sponsor | CENTOGENE GmbH Rostock |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 75 |
| Start date | 13 January 2020 |
| Primary completion | 31 May 2021 |
| Estimated completion | 31 May 2021 |
| Sites | 1 location across United States |
Conditions studied
- Pyruvate Kinase Deficiency — all drugs for Pyruvate Kinase Deficiency →
Sponsor
CENTOGENE GmbH Rostock
Who can join
Adults 5 to 30, any sex, with Pyruvate Kinase Deficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pyruvate kinase deficiency (PKD) is the most common red cell glycolytic enzyme defect causing hereditary non-spherocytic hemolytic anemia, caused by mutations in the PKLR gene. The main goal of this study is the diagnosis of pyruvate kinase deficiency in patients who exhibit chronic anaemia and/or splenomegaly and/or judiance and/or hyperbilirubinemia and/or history of prolonged neonatal jaundice and/ or cholelithiasis of undetermined aetiology.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03866590
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pyruvate Kinase Deficiency
Currently open trials in the same condition.
- NCT04902833 — Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms · active not recruiting
- NCT03481738 — Pyruvate Kinase Deficiency Global Longitudinal Registry · active not recruiting
Other CENTOGENE GmbH Rostock trials
Trials by the same sponsor.
- NCT06040008 — Investigating the Impact of Environmental Factors on the Transcriptomics Profile in Healthy Individuals · completed
- NCT05075187 — Epidemiological Study in FRONtoTemporal Dementia · completed
- NCT04925804 — Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) · completed
- NCT04548921 — Biomarker for Friedreich's Ataxia (BioFridA) · unknown
- NCT04091113 — Hereditary Angioedema Kininogen Assay · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03866590 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CENTOGENE GmbH Rostock
- Last refreshed: 9 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03866590.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing